Research Square · Sep 21, 2026
GLP-1 Receptor Agonist Exposure and Diabetic Retinopathy Progression: An American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) Analysis
By Ross C, Parmar UPS, Gong D et al.
Purpose To evaluate the association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) exposure and diabetic retinopathy (DR) progression, and the risk of requiring advanced intervention, among patients with type 2 diabetes mellitus (T2DM). Design: Retrospective cohort study. Participants: Using the IRIS® Registry (Intelligent Research in Sight), we identified eyes from patients with T2DM and DR with at least two International Classification of Diseases (ICD)-10 coded DR encounters and at least one pharmacy fill on or before the index DR date, between January 1, 2016, and October 1, 2025. Eyes of patients with GLP-1 RA exposure, panretinal photocoagulation (PRP), or pars plana vitrectomy (PPV) before the index date were excluded. Methods GLP-1 RA exposure was modeled as a time-varying covariate, with eyes classified as exposed beginning 90 days after the first prescription fill to capture sustained treatment. We performed 1:1 propensity score matching on demographic, socioeconomic, ocular, systemic, and diabetes-medication covariates, and fitted multivariable time-varying Cox proportional hazards models with standard errors clustered by patient. Main Outcome Measures: Time to progression from non-proliferative DR (NPDR) to proliferative DR (PDR) (primary); time to progression from mild or moderate to severe NPDR; and time to first PRP and PPV. Results A total of 1,716,975 eyes from patients with diabetic retinopathy met initial eligibility criteria, including 175,168 eyes with GLP-1 RA exposure and 1,541,807 without documented exposure. After 1:1 propensity score matching, the analytic cohort comprised 350,336 eyes, with 175,168 eyes per group, followed over 1,308,490 person-years. During follow-up, there were 13,666 PDR progression events, 2,290 severe NPDR progression events, 29,084 PRP events, and 6,806 PPV events. GLP-1 RA exposure was not associated with progression to PDR (hazard ratio [HR] 0.96, 95% confidence interval [CI] 0.92–1.01, P = 0.249) or to severe NPDR (HR 1.03, 95% CI 0.90–1.17, P = 0.762). Exposure was associated with a modest increase in the hazard of PRP (HR 1.07, 95% CI 1.03–1.12, P = 0.004) but not PPV (HR 1.07, 95% CI 1.00-1.15, P = 0.054). Model-standardized cumulative incidence estimates showed minimal absolute differences between exposure groups across all outcomes. Conclusions In this longitudinal national registry cohort, GLP-1 RA exposure was not associated with accelerated DR progression.